Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Your safety and informed consent are non-negotiable priorities at BlueWater
Holly Lofton from NYU Grossman School of Medicine highlights: "If a patient has recurrence of a previously resolved medical condition or if they gain more than 5% weight above their goal weight, then they are likely to continue to gain weight [and may need to restart]." This personalized approach ensures your tapering process is carefully monitored and adjusted as needed
doi: 10.1186/s12967-023-04111-9 49 ChenXShenJJiangXPanMChangSLiJet al
The SURMOUNT-1 trial evaluating tirzepatide for obesity demonstrated even greater weight reductions, with participants losing up to 20% of body weight at the highest dose
US$ 25.82
US$ 22.87
US$ 24.76
